Reports Q4 revenue $385.4M, consensus $367.18M. Given the proposed acquisition of Penumbra (PEN) by Boston Scientific (BSX), the company will not be providing financial guidance for the full year 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN: